Navigation Links
Chimerix Honored With "2011 Southeast BIO Deal of the Year: Venture Capital Transaction" Award
Date:11/7/2011

tics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  

The company's lead candidate, CMX001, is a broad spectrum, oral antiviral agent being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, preemption and treatment of double-stranded DNA (dsDNA) viruses, such as herpesviruses, adenoviruses, and orthopoxviruses. To date, more than 650 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols, including over 350 individuals who have received CMX001 under Emergency Investigational New Drug Applications (EINDs) or as part of the CMX001-350 Open-Label Study to help treat life-threatening dsDNA viral diseases for which there are no other therapeutic options.  

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of CMV in adult hematopoietic stem cell transplant patients (CMX001-201); a Phase 2 study for the treatment of adenovirus infection in pediatric and adult hematopoietic stem cell transplant patients (AdV HALT Trial/CMX001-202); and an Open-Label Study (CMX001-350) for the treatment of dsDNA viral infections.  The Open-Label Study builds on Chimerix's extensive experience working with over 150 clinicians at over 80 leading institutions in the United States, Canada, Europe, and Israel who have sought CMX001 under EINDs for the treatment of immunocompromised patients.  

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release, including the potential to provide an important therapeutic option for the 80 million people in the U.S. currently estimated to be immunocompromised and thus not candidates to receive a smallpox vaccine.  Chimerix has received federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Inst
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  BioElectronics Corporation (OTC Pink: BIEL), the ... on the FDA panel meeting for non-thermal shortwave diathermy: ... Pulsed Shortwave Therapy Meeting was held on May 21, ... The focus of the meeting was very narrow, in ... solely on the application of non-thermal shortwave diathermy for ...
(Date:5/23/2013)... , May 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization of novel ... as primary biliary cirrhosis, today announced that ... Officer, will present at the Deutsche Bank Securities 38th ... on Wednesday, May 29, 2013 at 4:10 p.m. ...
(Date:5/23/2013)...  Inhibikase Therapeutics, Inc., an emerging leader in ... present new results on its antiviral program to ... the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, ... the causative agent of Progressive Multifocal Leukoencephalopathy (PML). ... extended release formulation, can clear JC polyomavirus (JCV) ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2
... Oct. 7 Nile Therapeutics, Inc. (Nasdaq: ... of novel therapeutics for cardiovascular disease, today announced that ... Advisory Board overseeing the development of CD-NP, a dual ... of acute decompensated heart failure. Dr. ...
... Reportlinker.com announces that a new market research report ... RIS/PACS Market http://www.reportlinker.com/p0306627/European-RIS/PACS-Market.html ... terms of the challenges faced by market participants, drivers ... the research service include an executive summary, overview of ...
Cached Medicine Technology:Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board 2Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board 3Reportlinker Adds European RIS/PACS Market 2Reportlinker Adds European RIS/PACS Market 3
(Date:5/23/2013)... Maintaining its commitment to improving life ... Campaign. Kicking off in the spirit of Better Sleep ... for everyone and to providing a therapeutic sleep experience, ... May is Better Sleep Month, a result of the ... due to the Centers for Disease Control’s confirmation that ...
(Date:5/23/2013)... To kick off barbecue season, fire up the grill this ... with simple tips from Retrofit weight loss . Keep ... , “The powerful heat of the grill can be one ... not mindful of your selections, it can be as bad ... Margulies. , Margulies advises clients to choose healthy options from ...
(Date:5/23/2013)... May 23, 2013 Retül University ... proud to announce the formation of a strategic educational ... Technologies to offer a bike industry first “Positioned ... aerodynamic assessment for time trial, road and triathlon bike ... offered to bike fitters with a Retül University, F.I.S.T. ...
(Date:5/23/2013)... to moderate iodine deficiency during pregnancy may have a ... report. Low levels of the so-called "trace element" ... child at risk of poorer verbal and reading skills ... women can boost their iodine levels by eating enough ... finding, published online May 22 in The Lancet ...
(Date:5/23/2013)... of support for war influences soldier PTSD , ... heightened risk for developing post-traumatic stress disorder if public ... recent research. Social validation or invalidation shapes the level ... the researchers say. The study involved two experiments that ... grinder in one, having an actor show either ...
Breaking Medicine News(10 mins):Health News:DUXIANA®, Quality Bed Innovator, Celebrates Better Sleep Month and Launches Summer Health Campaign 2Health News:Fire It Up! Master Calories at the Grill with Retrofit Weight Loss 2Health News:Fire It Up! Master Calories at the Grill with Retrofit Weight Loss 3Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 2Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 3Health News:Low Prenatal Iodine May Affect Child's Brain Development 2Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 2Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 3
... could expose people to serious risks of injury and even death ... ,As lung cancer is the leading cause of cancer deaths among ... could save lives. But a study in New York seems to ... ,Dr. Peter B. Bach, a lung specialist and epidemiologist, who ...
... the number of amyloid plaques in the brains of ... like Alzheimer's. ,Roderic Eckenhoff, MD, Vice Chair ... Anesthesia and Critical Care, and his co-authors, report their ... of Aging. ,Every year over 100 million ...
... grow a genetically modified (GM) variety of rice from ... company behind the proposal, Ventria Bioscience, says the plants ... in infants. ,These plants, incorporating human genes ... some 3,000 acres (1,215 hectares) of farmland in the ...
... intake of soy isoflavones significantly reduced the risk of prostate ... cent//, says a new study. ,"To our knowledge, ... association between isoflavone and localized prostate cancer in Japanese, whose ... Kurahashi from Japan's National Cancer Center. ,Over half ...
... food industry representatives in Sydney has come out with the ... The move follows similar ones followed overseas by other food ... under pressure from the federal government to deal with the ... of trans fats in foods ,to be spelled out on ...
... faster than the current laboratory based detection, which may ... ,Sheila MacNeil and researchers at Sheffield University have ... bacteria in less then a minute by using light, ... ,The technology could have wide applications in wound healing, ...
Cached Medicine News:Health News:CT Scans may Not Benefit Lung Cancer Patients 2Health News:Inhaled Anesthetics Accelerate the Onset of Neurodegenerative Diseases Like Alzheimer's 2Health News:Soy Isoflavones Linked to Lower Prostate Cancer Risk 2
... are constructed of a patented ... polyvinyl acetal sponge. Each device ... to both surgeon and patient, ... firm enough to gently manipulate ...
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
... Ophthalmic Products provide the ... free products for unparalleled ... cleaning of fine microsurgical ... material is highly absorbent, ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Medicine Products: